Diabetic Retinopathy - Pipeline Review, H2 2011

Global Markets Direct, October 2011, Pages: 134

Diabetic Retinopathy - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Diabetic Retinopathy - Pipeline Review, H2 2011', provides an overview of the Diabetic Retinopathy therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Retinopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy. 'Diabetic Retinopathy - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Diabetic Retinopathy.
- A review of the Diabetic Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetic Retinopathy pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Diabetic Retinopathy therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Retinopathy Overview
Therapeutics Development
An Overview of Pipeline Products for Diabetic Retinopathy
Diabetic Retinopathy Therapeutics under Development by Companies
Diabetic Retinopathy Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Diabetic Retinopathy Therapeutics - Products under Development by Companies
Diabetic Retinopathy Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Diabetic Retinopathy Therapeutics Development
Alcon, Inc.
AstraZeneca PLC
Eli Lilly and Company
Oxford BioMedica plc
Novagali Pharma SA
Vitreoretinal Technologies Inc.
VasGene Therapeutics, Inc.
Alchemia Limited
Evotec Aktiengesellschaft
iCo Therapeutics Inc.
InNexus Biotechnology Inc.
Antisense Therapeutics Limited
Lpath, Inc.
Mesoblast Ltd
SANWA KAGAKU KENKYUSHO CO.,LTD.
Torrent Pharmaceuticals Limited
ThromboGenics NV
R-Tech Ueno, Ltd.
Paloma Pharmaceuticals, Inc.
Acucela Inc.
MAT Biopharma
OcuCure Therapeutics, Inc.
NormOxys, Inc.
Gene Signal International SA.
Promedior, Inc.
DiaKine Therapeutics, Inc.
Inotek Pharmaceuticals Corporation
NOXXON Pharma AG
Angstrom Pharmaceuticals, Inc.
Sirnaomics, Inc.
Resolvyx Pharmaceuticals, Inc
Charlesson LLC.
KAI Pharmaceuticals Inc.
TaiGen Biotechnology Co., Ltd.
Stelic Institute & Co.
AngioGenex, Inc.
Targa Therapeutics Corp.
Ampio Pharmaceuticals, Inc.
Diabetic Retinopathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Nevanac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATL1103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLG101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
A6 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RTU-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IXS312 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AGX1053 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cells For Diabetic Macular Edema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MS-553 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STP601 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VEGF/rGel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diabetic Retinopathy Therapeutics – Drug Profile Updates
Diabetic Retinopathy Therapeutics - Discontinued Products
Diabetic Retinopathy - Featured News
Oct 11, 2011: Antisense Completes Dosing In ATL1103 Phase I Clinical Trial
May 13, 2011: iCo Therapeutics Engages Ora For Ophthalmic Clinical And Regulatory Guidance
May 04, 2011: Promedior Presents Preclinical Data At ARVO Demonstrating PRM-151 Reduces Neovascularization In Retinal Diseases
Apr 19, 2011: Promedior Announces Presentation Of Data At ARVO Demonstrating PRM-151 Suppresses Choroidal And Retinal Neovascularization
Feb 23, 2011: iCo To Present iCo-007 Program At Retinal Physician Symposium 2011
Aug 09, 2010: Acucela Announces Publication Of ACU-4429 In Experimental Eye Research
Feb 05, 2010: Palomid 529 To cure Age-Related Vision Loss Reaches Phase I trials
Dec 16, 2009: Kanghong Invited Authoritative Experts To Fix The Late-Phase Clinical Trials Plan Of KH902
Dec 11, 2009: Summit plc., Awarded EUR 2.2million pounds from the Wellcome Trust
Oct 12, 2009: ATL1103 On Track To Move Into Clinical Development
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Global Diabetic Retinopathy Drug Pipeline Capsule - 2012
• Diabetic Complications
• HIV / AIDS – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013